Drug intelligence / Profile preview

bismuth preparation

Development stage: Preclinical
Lead developer: Chunfeng Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Bismuth preparation is an oral small molecule drug candidate currently in development by Beijing Chunfeng Pharmaceutical (Chunfeng Pharm) for the treatment of various cancers. While bismuth-based compounds are traditionally recognized for their use in treating gastrointestinal disorders such as peptic ulcers and Helicobacter pylori infections, this preparation is part of the company's innovative drug pipeline targeting antitumor indications. The specific chemical composition, molecular targets, and precise mechanism of action have not been publicly detailed by the developer, but the project represents an effort to leverage the unique properties of bismuth complexes in an oncological context.

Other names: 铋制剂bismuth preparation (Chunfeng Pharmaceutical)

Targets

Urease

Beyond the preview

Go deeper on bismuth preparation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bismuth preparation.

Explore the full profile